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ABSTRACT
1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] has many noncalcemic actions that rest on inhibition of proliferation and promotion of
differentiation in malignant and normal cell types. 1,25(OH)2D3 stimulates osteoblast differentiation of human marrow stromal cells
(hMSCs), but little is known about the effects of 25-hydroxyvitamin D3 [25(OH)D3] on these cells. Recent evidence shows that hMSCs
participate in vitamin D metabolism and can activate 25(OH)D3 by CYP27B1/1a-hydroxylase. These studies test the hypothesis that
antiproliferative and prodifferentiation effects of 25(OH)D3 in hMSCs depend on CYP27B1. We studied hMSCs that constitutively express
high (hMSCs
hi-1a) or low (hMSCs
lo-1a) levels of CYP27B1 with equivalent expression of CYP24A1 and vitamin D receptor. In hMSCs
hi-1a,
25(OH)D3 reducedproliferation, downregulated proliferating cellnuclear antigen(PCNA), upregulated p21
Waf1/Cip1, anddecreased cyclin
D1. Unlike 1,25(OH)2D3, the antiapoptotic effects of 25(OH)D3 on Bax and Bcl-2 were blocked by the P450 inhibitor ketoconazole. The
antiproliferative effects of 25(OH)D3 in hMSCs
hi-1a and of 1,25(OH)2D3 in both samples of hMSCs were explained by cell cycle arrest, not
by increased apoptosis. Stimulation of osteoblast differentiation in hMSCs
hi-1a by 25(OH)D3 was prevented by ketoconazole and upon
transfection with CYP27B1 siRNA. These data indicate that CYP27B1 is required for 25(OH)D3’s action in hMSCs. Three lines of evidence
indicate that CYP27B1 is required for the antiproliferative and prodifferentiation effects of 25(OH)D3 on hMSCs: Those effects were not
seen (1) in hMSCs with low constitutive expression of CYP27B1, (2) in hMSCs treated with ketoconazole, and (3) in hMSCs in which
CYP27B1 expression was silenced. Osteoblast differentiation and skeletal homeostasis may be regulated by autocrine/paracrine actions
of 25(OH)D3 in hMSCs.  2011 American Society for Bone and Mineral Research.
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Introduction
V
itamin D is an important regulator of mineral and bone
metabolism, and it is now appreciated that its metabolites
and analogues have many other actions. Calcitriol, or 1a,25-
dihydroxyvitamin D3 [1,25(OH)2D3], is the most active metabo-
lite, with high affinity for the nuclear vitamin D receptor (VDR).
(1)
It is produced in the kidney by the 1a-hydroxylation of the
precursor 25-hydroxyvitamin D3 [25(OH)D3] by the cytochrome
P450 enzyme CYP27B1/1a-hydroxylase.
(2) Hydroxylation of
vitamin D metabolites at the carbon 24 position by 25-
hydroxyvitamin D–24-hydroxylase (CYP24A1) is the first step
in their inactivation and excretion. Basal expression of CYP24A1
is usually low but is highly induced by 1,25(OH)2D3.
(1)
Calcitriol has major effects in inhibiting proliferation and promot-
ing differentiation of many cell types, especially tumor cells such as
human breast cancer cells,
(3) colon sarcoma cells,
(4) prostate cancer
cells, colorectal adenoma, and carcinoma cells.
(5) Epidemiologic and
experimental studies also indicate that 1,25(OH)2D3 has antitumor
effects
(6); those effects are attributed to the inhibition of
proliferation,
(5,7,8) arrest of cell cycle,
(3,9) increase in apopto-
sis,
(4,10,11) and induction of differentiation.
(12,13) The antiproli-
ferative and prodifferentiation effects of 1,25(OH)2D3 also have
been demonstrated for some nonmalignant cell types, such as
humanperipheralmonocytes.
(14,15) Littleis known,however, about
the effects of 25(OH)D3 on cell proliferation and differentiation.
In addition to kidney tubule cells, other human cells, notably
osteoblasts
(16) and their progenitors in the bone marrow,
(17)
produce 1,25(OH)2D3. Bone cells participate in vitamin D
metabolism and also are targets of 1,25(OH)2D3 action.
(17) The
differentiation of human marrow stromal cells (hMSCs, aka
mesenchymal stem cells)
(18) and rat osteogenic ROS 17/2 cells
(19)
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1145to osteoblasts is stimulated by 1,25(OH)2D3. Less is known about
the effects of 25(OH)D3 on bone cells. In recent studies with
freshly isolated hMSCs from 19 subjects, 1,25(OH)2D3 stimulated
osteoblast differentiation in all samples, and 25(OH)D3 did so in
two-thirds of them.
(17) The variability in response to 25(OH)D3
may be due to differences in expression of CYP27B1. The
combined presence of CYP27B1 and VDR indicates possible
autocrine/paracrine roles for 25(OH)D3 in hMSCs. This study tests
the hypothesis that the antiproliferative and prodifferentiation
effects of 25(OH)D3 in hMSCs depend on CYP27B1.
Materials and Methods
Cells and reagents
Bone marrow samples were obtained with institutional review
board approval as femoral tissue discarded during primary hip
arthroplasty for osteoarthritis. A series of samples from
22 subjects (average age is 58 15 years) was prepared and
screened. Low-density marrow mononuclear cells were isolated
by centrifugation on Ficoll/Histopaque 1077 (Sigma, St Louis,
MO, USA).
(20) This procedure removes differentiated cells and
enriches for undifferentiated low-density marrow mononuclear
cells that include a population of nonadherent hematopoietic
cells and a fraction capable of adherence and differentiation into
musculoskeletalcells.Thenonadherenthematopoieticstemcells
were rinsed away 24hours after seeding, and the adherent
hMSCs were expanded in monolayer culture with standard
growth medium, phenol red–free a modified essential medium
a-MEM), 10% fetal bovine serum–heat inactivated (FBS-HI), 100
U/mL of penicillin, and 100mg/mL of streptomycin (Invitrogen,
Carlsbad, CA, USA). All samples were used at passages 2 through
4. Some experiments used standard osteogenic medium (ie,
phenol red–free a-MEM, 10% FBS-HI, 100 U/mL of penicillin,
100mg/mL of streptomycin, 10nM dexamethasone, 5mM
b-glycerophosphate, and 50mg/mL of ascorbate-2-phosphate)
or osteogenic medium (ie, phenol red–free a-MEM, 1% FBS-HI,
100 U/mL of penicillin, 100mg/mL of streptomycin, 10nM
dexamethasone, 5mM b-glycerophosphate, and 50mg/mL of
ascorbate-2-phosphate). After transfection with siRNA, all media
used were without 100 U/mL of penicillin and 100mg/mL of
streptomycin. Reagents such as 25(OH)D3, 1,25(OH)2D3, and
ketoconazole were purchased from Sigma; each was prepared as
a stock solution at 10
 3 M in absolute ethanol and stored at
 808C.Inpreliminary dose-findingstudies(datanotshown) with
Western immunoblotting, we found no responses to 1, 10, or
100nM 25(OH)D3 and responses to 1000nM 25(OH)D3; thus
most experiments used 1000nM 25(OH)D3. In all 3-day
experiments, vitamin D metabolites were added daily to control
for inactivation by 24-hydroxylation.
RNA isolation and RT-PCR
Total RNA was isolated from human MSCs with TRIZOL reagent
(Invitrogen). For reverse-transcriptase polymerase chain reaction
(RT-PCR), 2mg of total RNA was reverse-transcribed into cDNA
with SuperScript II (Invitrogen) following the manufacturer’s
instructions. Concentrations of cDNA and amplification condi-
tions were optimized for each gene product to reflect the
exponential phase of amplification. One-twentieth of the cDNA
wasusedineach50-mLPCRreaction(30to40cyclesof948Cfor1
minute, 55 to 608C for 1 minute, and 728C for 2minutes), as
described previously.
(20) Gene-specific primer pairs (Table 1) for
CYP27B1,
(17)CYP24A1,
(17)VDR,
(17)Cbfa1/Runx2(Runx2),
(21)AlkP,
(21)
bone sialoprotein (BSP),
(21) Bax,
(21) and Bcl-2
(22) were used for
amplification. PCR products were separated by agarose gel
electrophoresis and were quantified by densitometry of
captured gel images with a Kodak Gel Logic 200 Imaging
System and Kodak Molecular Imaging Software following the
manufacturer’s instructions (Kodak Molecular Imaging Systems,
Table 1. Primer Sets Used for RT-PCR
Accession number Primer name Sequence (5’!3’) Product size (bp)
NM_000785.3 CYP27B1 F¼GCTACACGAGCTGCAGGTGCAGGGC 252
R¼AGCGGGGCCAGGAGACTGCGGAGCC
NM_001128915.1 CYP24A1 F¼GCAGCCTAGTGCAGATTT 335
R¼ATTCACCCAGAACTGTTG
NM_001017535.1 VDR F¼AGCCTCAATGAGGAG CACTCCAAG 208
R¼ACGGGTGAGGAGGGCTGCTGAGTA
NM_004324.3 Bax F¼GAGGATGATTGCCGCCGTGGAC 279
R¼CGGTGGTGGGGGTGAGGAGG
NM_000633.2 Bcl-2F ¼CTTTCCATGTTGTTGGCCGGATCA 137
R¼CCCAGGGCAAAGAAATGCAAGTGA
NM_001015051.3 Runx2 F¼GTTTGTTCTCTGACCGCCTC 318
R¼CCAGTTCTGAGGCACCTGAAA
NM_000478.4 AlkP F¼GCGAACGTATTTCTCCAGACCCAG 369
R¼TTCCAAACAGGAGAGTCGCTTCA
NM_004967 BSP F¼TCAGCATTTTGGGAATGGCC 657
R¼GAGGTTGTTGTCTTCGAGGT
NM_002046.3 GAPDH F¼TGATGACATCAAGAAGGTGGTGAAG 240
R¼TCCTTGGAGGCCATGTGGGCCAT
1146 Journal of Bone and Mineral Research GENG ET AL.Rochester, NY, USA). Data were expressed by normalizing the
densitometric units to GAPDH (internal control).
In vitro biosynthesis of 1,25(OH)2D3 by hMSCs
For comparing synthesis of 1,25(OH)2D3, hMSCs (three replicate
wells)werecultivatedin12-wellplatesuntilconfluence,andthen
the medium was changed to serum-free a-MEM supplemented
with 1% insulin-transferrin-selenium plus linoleic-bovine serum
albumin (ITS)
þ1,1 0 mM 1,2-dianilinoethane (N,N’-diphenylethy-
lene diamine; Sigma) and treated with or without 1000nM
25(OH)D3 for 24hours.
(17) This concentration of substrate
25(OH)D3 is customary for in vitro biosynthesis studies.
(17,23)
1,2-Dianilinoethane was added to the cultures as an antioxidant.
Supernatants were harvested and stored at  208C prior to
analysis for 1,25(OH)2D3 content. The 1,25(OH)2D3 levels in the
media were determined quantitatively with a 1,25(OH)2D3 EIA kit
(Immunodiagnostic Systems, Ltd., Fountain Hills, AZ, USA)
according to the manufacturer’s instructions. The hMSCs were
lysedwith a buffer containing 150mM NaCl, 3mMNaHCO3, 0.1%
Triton X-100, and a mixture of protease inhibitors (Roche
Diagnostics, Mannheim, Germany). Protein concentration was
determined with the BCA System (Thermo Fisher Scientific,
Rockford, IL, USA). The CYP27B1 activity was expressed as
biosynthesized 1,25(OH)2D3 in medium per milligram of protein
per hour (femtomoles per milligram of protein per hour).
Proliferation
Human MSCs (hMSCs
hi-1a and hMSCs
lo-1a) at passage 2 were
seeded at 3000/cm
2 in 12-well plates. Cells were cultured in
replicate(12replicatewells)instandardgrowthmedium (10%FBS-
HI) in the absence or presence of 1, 10, or 100nM 1,25(OH)2D3 or
25(OH)D3 for 3 days. Cells were suspended with 0.5mL of 0.05%
trypsin-ethylenediamine tetraacetic acid (Invitrogen), and cell
number was determined by hemacytometer.
Western immunoblot
Human MSCs were cultured in 100-mm dishes in standard
growth medium (10% FBS-HI). At 50% confluence, the cells were
treated with 1, 10, 100nM 1,25(OH)2D3 or 1000nM 25(OH)D3 for
3 days. Whole-cell lysates were prepared with lysis buffer
(150mM NaCl, 3mM NaHCO3, 0.1% Triton X-100, and a mixture
of protease inhibitors; Roche Diagnostics, Mannheim, Germany)
and were homogenized with a pestle (Kontes, Vineland, NJ, USA)
and centrifuged at 16,000g (Eppendorf centrifuge; Eppendorf,
Hamburg, Germany). Protein concentration was determined
(BCA system; Thermo Fisher Scientific). Western immunoblotting
was performed as described previously.
(20) In brief, proteins were
resolved on 4% to 12% SDS-PAGE (NuPAGE Bis-Tris gel;
Invitrogen) and transferred onto polyvinylidene fluoride mem-
branes (PVDF; Amersham Biosciences, Piscataway, NJ, USA). The
membranes were blocked with 5% nonfat milk in PBS buffer
containing 0.1% Tween-20 (PBST) for 2 to 3hours at room
temperature and incubated at 48C overnight with primary
antibodies proliferating cell nuclear antigen (PCNA) (1:3000;
Abcam, Cambridge, UK), CYP27B1 (H-90, 1:1000; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), b-actin (1:8000, Santa
Cruz Biotechnology, Inc.), and Bax, Bcl-2, p21
Waf1/Cip1, and cyclin
D1 (each at 1:1000; Cell Signaling Technology, Beverly, MA, USA).
After removal of the unbound primary antibodies by three
5-minute washes with PBST, the membranes were incubated
with horseradish peroxidase–conjugated secondary antibodies
(1:5000) for 1 hour at room temperature and washed three times
for 5minutes with PBST. The antibody-associated protein bands
were revealed with the ECL-plus Western blotting system
(Amersham Biosciences).
Alkaline phosphatase (AlkP) enzymatic activity assay
For AlkP enzymatic activity assay, the concentration of serum in
standard osteogenic medium (10% FBS-HI) was reduced to 1%
FBS-HI to minimize possible subsequent differences in prolifera-
tion that could confound interpretation of the effects of vitamin
D metabolites on osteoblastogenesis. The medium was changed
every 2 days. AlkP enzyme activity was measured spectro-
photometrically, as described previously.
(21) Protein concentra-
tion was determined with the BCA system (Thermo Fisher
Scientific, Inc.). The AlkP enzyme activity was expressed as
micromoles per minute per gram of protein, and some was
calculated as the ratio of treated relative to control.
RNA interference with CYP27B1 siRNA
Transient transfection of siRNA into hMSCs
hi-1a was performed
byelectroporation withthe HumanMSCNucleofector Kit(Lonza/
Amaxa Biosystems, Walkersville, MD, USA) with either CYP27B1
siRNA,nonsilencingcontrolsiRNA(anonhomologous,scrambled
sequence equivalent; Santa Cruz Biotechnology, Inc.), or PBS
according to the manufacturer’s instructions and as described
previously.
(24) In brief, hMSCs
hi-1a were harvested by trypsiniza-
tion and resuspended at 10
6 cells in 100mL of Nucleofector
Solution (Lonza/Amaxa Biosystems) with 10 or 100pmol of
CYP27B1 siRNA. Electroporation was performed in Nucleofector II
device with Program U-23 (Lonza/Amaxa Biosystems). Immedi-
ately after electroporation, the cells were transferred to 60-mm
dishes or 12-well plates in phenol red–free a-MEM and 10%
FBS-HI. Some cells were collected at 80% confluence for RT-PCR
or Western immunoblot analysis to determine the effect of
CYP27B1 siRNA. Some cells that were cultured until confluent
in the 12-well plates were treated with or without 1000nM
25(OH)D3 in serum-free a-MEM supplemented with 1% ITS
þ1,
10mM 1,2-dianilinoethane (N,N’-diphenylethylene diamine) for
24hours to assess 1a-hydroxlyase activity. Cellular 1,25(OH)2D3
production was determined by EIA as described under ‘‘In vitro
biosynthesis of 1,25(OH)2D3 by hMSCs.’’ At 24hours after
electroporation, some cells were treated with either 25(OH)D3
(1000nM) or vehicle control (ethanol) daily in standard growth
medium (10% FBS-HI) for another 72hours for RT-PCR assays.
Whensomecellsinthe12-wellplateswerenearly80%confluent,
the medium was changed to the osteogenic medium with 1%
FBS-HI 10nM 25(OH)D3 for 7 days for assessment of alkP
enzymatic activity as another index of osteoblast differentiation.
Statistical analysis
Experiments were performed at least in triplicate. Group data are
presented as mean SEM unless otherwise indicated. Quanti-
tative data were analyzed with nonparametric tools, either the
Mann-Whitney test or Spearman correlation test. If data allowed,
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way ANOVA for multiple group comparisons or Pearson
correlation test. A value of p<.05 was considered significant.
Results
Expression of CYP27B1 and CYP24A1 genes and
1a-hydroxylase activity in hMSCs
Gene expression analysis with hMSCs from 22 subjects showed a
wide range of constitutive expression of CYP27B1 (Fig. 1A,
showing 7 representative samples). Two samples of hMSCs were
selected for detailed studies, having either high (hMSCs
hi-1a,
from a 42-year-old man) or low (hMSCs
lo-1a, from a 46-year-old
man) levels of CYP27B1, with equivalent expression of CYP24A1
and VDR (Fig. 1B). Their activity for 1a-hydroxylation was
comparedbymeasuringproductionof1,25(OH)2D3.Biosynthesis
of 1,25(OH)2D3 in the hMSCs
hi-1a was 2.98-fold greater that in the
hMSCs
lo-1a (4433.4 versus 1487.9 fmol/mg protein per hour,
p<.0001; Fig. 1C). Upregulation of CYP24A1 by 1,25(OH)2D3
(1, 10, and 100nM) or 25(OH)D3 (1000nM) treatment was
equivalent in both specimens of hMSCs (Fig. 1D).
Relative antiproliferative effects of 25(OH)D3 and
1,25(OH)2D3 on hMSCs
Two samples of hMSCs were cultured for 3 days after seeding in
standard growth medium (10% FBS-HI). There was less cellularity
in cultures of both hMSCs
hi-1a and hMSCs
lo-1a treated with
100nM 1,25(OH)2D3 compared with vehicle control. In contrast,
only the hMSCs
hi-1a were inhibited by 25(OH)D3 (Fig. 2A). There
Fig. 1. Expression of CYP27B1 and CYP24A1 genes and 1a-hydroxylase
activity in hMSCs. (A) Gel electrophoretogram shows RT-PCR products
CYP27B1, VDR, and GAPDH in 7 representative specimens of hMSCs.
Labels for lanes indicate age and gender. (B) Gel electrophoretogram
shows RT-PCR products for CYP27B1, CYP24A1, VDR, and GAPDH in
selected hMSCs
hi-1a (from a 42-year-old man) and hMSCs
lo-1a (from a
46-year-old man). (C) 1,25(OH)2D3 synthesis was measured in hMSCs
hi-1a
and hMSCs
lo-1a. Cultures were treated with or without1000nM 25(OH)D3
in serum-free a-MEM supplemented with 1% ITS
þ1,1 0 mM 1,2-dianili-
noethane (N,N’-diphenylethylene diamine) for 24hours. Cellular
1,25(OH)2D3 production (three replicate wells) was determined by EIA.
There was no detectable (ND) 1,25(OH)2D3 in cultures without 25(OH)D3
exogenous substrate.
   p<.001. (D) Gel electrophoretogram shows RT-
PCR products for CYP24A1 and GAPDH in hMSC
hi-1a and hMSC
lo-1a
cultures after 3 days in standard growth medium with 10% FBS-HI in
the absence or presence of 1,25(OH)2D3 or 25(OH)D3.
Fig. 2. Relative effects of 25(OH)D3 and 1,25(OH)2D3 on proliferation of
hMSCs. (A) Photomicrographs show hMSC
hi-1a and hMSC
lo-1a cultures
after 3 days in the absence or presence of 100nM 1,25(OH)2D3 or
25(OH)D3 ( 200 magnification). (B) Cell number was determined in
hMSC
hi-1a and hMSC
lo-1a cultures after 3 days in the absence or presence
of 1, 10, 100nM 1,25(OH)2D3 or 25(OH)D3. Results are expressed as
mean SEM (12 replicate wells).
 p<.05;
  p<.01;
   p<.001. (C) Wes-
tern immunoblots show proliferating cell nuclear antigen and b-actin
levels in hMSC
hi-1a and hMSC
lo-1a cultures after 3 days in the absence or
presence of 1,25(OH)2D3 or 25(OH)D3.( D) Western immunoblots show
p21, cyclin D1, and b-actin in hMSC
hi-1a and hMSC
lo-1a cultures after 3
days in the absence or presence of 1,25(OH)2D3 or 25(OH)D3.
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forboth cell preparations(Fig.2B). Both 25(OH)D3and 1,25(OH)2D3
inhibited proliferation of hMSCs
hi-1a; there was a significant
inhibition of proliferation of hMSCs
hi-1a at 100nM of 25(OH)D3
(56% of control cell number, p<.001) and 1,25(OH)2D3 (50%;
p<.001). In contrast, hMSCs
lo-1a were resistant to 25(OH)D3
(96%) yet were inhibited by 1,25(OH)2D3 (17%, p<.001; Fig. 2B).
Consistent with the effects on cell numbers, PCNA was
downregulated by 1,25(OH)2D3 in hMSCs
hi-1a and in hMSCs
lo-1a
(Fig. 2C). With 25(OH)D3 treatment, PCNA in hMSCs
hi-1a was
64.9% of control, but for hMSCs
lo-1a, PCNA was equivalent to
control. With hMSCs
hi-1a, both 25(OH)D3 and 1,25(OH)2D3
downregulated cyclin D1 and upregulated the negative
regulator p21
Waf1/Cip1 (Fig. 2D). In hMSCs
lo-1a, the effects of
1,25(OH)2D3 on cell cycle regulators were similar to those for
hMSCs
hi-1a, but there were no effects by 25(OH)D3.
Relative effects of 25(OH)D3 and 1,25(OH)2D3 on
Bax/Bcl-2 ratios in hMSCs
Mechanisms involved in the relative effects of 25(OH)D3 and
1,25(OH)D3 were studied by analysis of expression of apoptosis-
associated proteins. First, effects of metabolites were compared
in hMSCs
hi-1a and hMSCs
lo-1a. In hMSCs
hi-1a, both 25(OH)D3 and
1,25(OH)2D3 induced a downregulation of Bax and an
upregulation of the Bcl-2 protein (Fig. 3A); these effects resulted
in lower Bax/Bcl-2 ratios with 100nM 1,25(OH)2D3 (20% com-
pared with vehicle control) and with 1000nM 25(OH)D3 (43%). In
hMSCs
lo-1a, the Bax/Bcl-2 ratio was lower with 100nM 1,25(OH)2D3
(19%), but there was essentially no effect by 25(OH)D3 (95%). The
effectsonmRNAlevelsofBaxandBcl-2 (Fig.3B)correspondedwith
the changes observed for protein levels (Fig. 3A).
As a second approach, the cytochrome P450 inhibitor
ketoconazole was used to determine the importance of
hydroxylationon25(OH)D3effectsonproliferation.Ketoconazole
(10mM) diminished the effects of 25(OH)D3 (1000nM) and not
the effects of 1,25(OH)2D3 (10nM) on Bax and Bcl-2 in hMSCs
hi-1a
(Fig. 3C). In the presence of 25(OH)D3, the Bax/Bcl-2 ratio was
27% of that with vehicle control, and the decrease by 25(OH)D3
was blocked by ketoconazole (90%). In the presence of
1,25(OH)2D3, the Bax/Bcl-2 ratio was 36% of that with vehicle
control, similar to that with 1,25(OH)2D3 and ketoconazole (37%).
Relative effects of 25(OH)D3 and 1,25(OH)2D3 on
osteoblast differentiation in hMSCs
Regulation of osteoblast differentiation was quantified first by
AlkP enzymatic activity assays in osteogenic medium with 1%
FBS-HI (Fig. 4A). In hMSCs
hi-1a, there was similar stimulation of
AlkP activity by 25(OH)D3 (2.16-fold, p¼.0003) and by
1,25(OH)2D3 (1.77-fold, p<.0001). In contrast, with hMSCs
lo-1a,
25(OH)D3 had no effect (0.96-fold, p¼.577), and 1,25(OH)2D3
stimulated AlkP activity (1.86-fold, p<.0001).
Osteoblast differentiation was also monitored by osteoblast
signature genes (ie, Runx2, AlkP, and BSP) after transfer to
standard osteogenic medium (10% FBS-HI) or after addition of
1,25(OH)2D3 to standard growth medium (10% FBS-HI). As
expected, there was time-dependent upregulation of Runx2,
AlkP, and BSP in hMSCs
hi-1a in standard osteogenic medium
(Fig. 4B). Addition of 1,25(OH)2D3 to standard growth medium
also upregulated osteoblast genes in hMSCs
hi-1a (Fig. 4C).
Addition of 25(OH)D3 to standard growth medium also
upregulated osteoblast genes in hMSCs
hi-1a, but its effect was
diminished by ketoconazole (Fig. 4D).
Effect of CYP27B1 siRNA on the stimulation of osteoblast
differentiation by 25(OH)D3
As another approach to assess the mechanism by which
25(OH)D3 can stimulate osteoblast differentiation, hMSCs
hi-1a
were engineered to have reduced constitutive expression of
CYP27B1. There were no noticeable differences in cell density or
appearance of control cells (electroporation with PBS), cells
treated with nonsilencing control siRNA, and cells with 10 or
100pmol CYP27B1 siRNA (Fig. 5A). Transient transfection of
CYP27B1 siRNA into hMSCs
hi-1a resulted in reductions of CYP27B1
mRNA (2% of control; Fig. 5B) and CYP27B1 protein (11% of
control; Fig. 5C). No effect was shown with a nonsilencing,
scrambled siRNA sequence (lane NC in Fig. 5B, C). The amount of
1,25(OH)2D3 synthesized by the cells transfected with CYP27B1
Fig. 3. Relative effects of 25(OH)D3 and 1,25(OH)2D3 on Bax/Bcl-2 ratios
in hMSCs. (A) Western immunoblots show Bax, Bcl-2, and b-actin in
hMSC
hi-1a and hMSC
lo-1a cultures after 3 days in the absence or presence
of1,25(OH)2D3or25(OH)D3.ThebargraphsrepresenttheBax/Bcl-2ratios
after each densitometric value was normalized to b-actin. (B) Gel elec-
trophoretograms show RT-PCR products for Bax, Bcl-2, and GAPDH in
hMSC
hi-1a and hMSC
lo-1a cultures after 3 days in the absence or presence
of 1, 10, or 100nM 1,25(OH)2D3 or 1000nM 25(OH)D3.( C) Gel electro-
phoretogram shows RT-PCR products for Bax, Bcl-2, and GAPDH in
hMSCs
hi-1a after 3 days in the absence or presence of 10nM
1,25(OH)2D3 or 1000nM 25(OH)D3 10mM ketoconazole.
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siRNA (1075 versus 4786 fmol/mg protein per hour, p<.0001;
Fig. 5D). Treatment with 25(OH)D3 upregulated Runx2, AlkP, and
BSP in both control preparations of hMSCs
hi-1a. With cells
transfected with CYP27B1 siRNA, however, 25(OH)D3 had no
effect on osteoblast genes (Fig. 5E). As a functional marker of
osteoblast differentiation, we measured AlkP enzymatic activity
after 7 days in osteogenic medium (1% FBS-HI). Whereas
25(OH)D3 stimulated AlkP activity of control cells (1.87-fold,
p<.0001), there was no effect in cells transfected with CYP27B1
siRNA (1.04-fold, p¼.093; Fig. 5F).
Discussion
This study used three approaches to examine the role of
CYP27B1 on the effects of 25(OH)D3 in hMSCs. First, we
compared cells with high and low constitutive expression of
CYP27B1. Finding a wide range of expression in hMSCs from 22
subjects is consistent with our previous studies.
(17) The level of
CYP27B1 expression was found to be related to the vitamin D
status
(17) and, more recently, to age
(25) of the subjects. There is
growing evidence that hMSCs
(17) and human bone cells
(26) are
both sources and targets of1,25(OH)2D3, and thus vitamin Dmay
have multiple autocrine/paracrine actions in bones.
It was important to control for 24-hydroxylation in these
studies because differences in inactivation of added vitamin D
metabolites could confound interpretation. The activities of
CYP27B1 and CYP24A1 are important for the maintenance of
appropriate levels of 1,25(OH)2D3 and 25(OH)D3. Therefore, two
Fig. 4. Comparisonofeffectsof25(OH)D3and1,25(OH)2D3onosteoblast
differentiation in hMSCs. (A) Alkaline phosphatase enzymatic activity (6
replicate wells) was measured in hMSCs
hi-1a and hMSCs
lo-1a in the
absence or presence of 10nM 1,25(OH)2D3 (open bars) or 25(OH)D3
(closed bars) in osteogenic medium with 1% FBS-HI for 7 days. Results
are reported relative to control (Rx/control) with horizonal dashed line as
1.0; mean SEM. (B) Gel electrophoretogram shows RT-PCR products of
osteoblast signature genes (Runx2, AlkP,a n dBSP)a n dGAPDH in hMSCs
hi-1a
after0,3,and7daysinstandardosteogenicmediumwith10%FBS-HI.(C)
Gel electrophoretogram shows RT-PCR products of osteoblast signature
genes (Runx2, AlkP, and BSP) and GAPDH in hMSCs
hi-1a after 3 days in the
absence or presence of 1, 10, or 100nM 1,25(OH)2D3 in standard growth
medium with 10% FBS-HI. (D) Gel electrophoretogram shows RT-PCR
products of osteoblast signature genes(Runx2, AlkP, and BSP) and GAPDH
in hMSCs
hi-1a after 3 days in the absence or presence of 1000nM
25(OH)D3 10mM ketoconazole in standard growth medium with
10% FBS-HI.
Fig. 5. Effect of CYP27B1 siRNA on the stimulation of osteoblast differ-
entiation by 25(OH)D3. Four groups were treated by electroporation with
PBS (C¼control), with nonsilencing control siRNA (NC), or with 10 or
100pmol of CYP27B1 siRNA. (A) Photomicrographs show cultures of
control and transfected hMSCs
hi-1a ( 200 magnification). (B) Gel electro-
phoretogram shows CYP27B1 and GAPDH in controls and in transfected
cells. (C) Western immunoblot shows CYP27B1 and b-actin protein levels
incontrolsandintransfectedcells.(D)Cellstransfectedwithnonsilencing
siRNA and 100pmol of CYP27B1 siRNA were treated with or without
1000nM 25(OH)D3 in serum-free a-MEM supplemented with 1% ITS
þ1,
10mM 1,2-dianilinoethane (N,N’-diphenylethylene diamine) for 24hours.
Cellular 1,25(OH)2D3 production was determined by EIA as described
under ‘‘In vitro biosynthesis of 1,25(OH)2D3 by hMSCs.’’ Results are shown
as the mean SEM (3 replicate wells). There was no detectable (ND)
1,25(OH)2D3 in cultures without 1000nM 25(OH)D3 exogenous substrate.
   p<.001. (E) Gel electrophoretogram shows Runx2, AlkP, BSP, and
GAPDH in controls and in transfected hMSCs
hi-1a after 3 days 1000nM
nM 25(OH)D3.(F) Alkaline phosphatase enzymatic activity was measured
incontrolandtransfectedhMSCs
hi-1a(100pmolofCYP27B1siRNA)after7
days 10nM 25(OH)D3 in osteogenic medium. Values represent the
mean SEM (6 replicate wells).
   p<.001.
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extremes in expression of CYP27B1 and equivalent expression of
CYP24A1 and VDR. Further, the expression of CYP24A1 was
found to be regulated with equivalence in both specimens of
hMSCs; this observation reduces concerns of confounding
effects of 24-hydroxylation in these studies. In addition, fresh
metabolites were added daily.
There were substantial differences in the synthesis of
1,25(OH)2D3 by hMSCs
hi-1a and hMSCs
lo-1a. The difference also
held for hMSCs with and without CYP27B1 gene silencing.
Although these experiments cannot be used to estimate what
would be the steady-state concentration of 1,25(OH)2D3 in the
bone marrow in different subjects whose cells have high or low
expression of CYP27B1, they provide evidence for a potential
autocrine/paracrine role for 25(OH)D3 metabolism in osteoblast
differentiation. Similar ideas have been proposed for 25(OH)D3
metabolism in regulating bone matrix formation by differen-
tiated human osteoblasts.
(23)
There was dose-dependent inhibition of proliferation by
25(OH)D3 with hMSCs that had a high level of expression of
CYP27B1; 25(OH)D3 reduced their proliferation and down-
regulated PCNA. There is some information about antiprolifera-
tive actions of 25(OH)D3 in other human cell types. In human
primary prostate epithelial cells that expressed CYP27B1, low
concentrations of 25(OH)D3 suppressed cell growth.
(27) In
prostatic cancer cells lacking CYP27B1, 25(OH)D3 failed to
demonstrate antiproliferative action.
(28) There are several
mechanisms mediating the antiproliferative effects of
1,25(OH)2D3. In U937 myelomonocytic cells, 1,25(OH)2D3 induces
an arrest in the G1 phase of the cell cycle that depends on upregu-
lation of the cyclin-dependent kinase inhibitor p21
Waf1/Cip1.
(29)
More recently, p21
Waf1/Cip1 was shown to be a primary
antiproliferative mediator for the VDR in the presence of its
ligand, 1,25(OH)2D3.
(30) Cyclin D1 is increased in dividing cells
during the G1phaseandisnecessaryforthetransitionfromG1to S
phase.
(31) VitaminDdecreasescyclinD1abundance and/or activity
by different mechanisms in different cell types. For example, in
human epidermoid A431 cells, 1,25(OH)2D3 inhibited transform-
i n gg r o w t hf a c t o ra (TGF-a)/endothelial growth factor receptor
(EGFR) transactivation of cyclin D1.
(32) We found that
25(OH)D3 downregulated cyclin D1 and upregulated the negative
regulator p21
Waf1/Cip1 in hMSCs
hi-1a. In contrast, 25(OH)D3 had
no such effects in hMSCs
lo-1a. The upregulation of p21
Waf1/Cip1
and decreased expression of cyclin D1 in hMSCs
hi-1a provide
mechanisms for the antiproliferative effect of 25(OH)D3.
1,25(OH)2D3 also affects the levels of proapoptotic (ie, Bax and
Bak) and antiapoptotic (ie, Bcl-2 and Bcl-XL) proteins, resulting in
apoptosis in several tumor models, including human carcinomas
of the breast, colon, and prostate.
(4,10,33) This study with hMSCs
indicates that the antiproliferation effects of 1,25(OH)2D3 or
25(OH)D3 are not explained by increases in Bax or decreases in
Bcl-2. In fact, the ratio of Bax/Bcl-2 decreases at both the mRNA
and protein levels. Two lines of evidence indicate that those
effects of 25(OH)D3 on Bax and Bcl-2 depend on CYP27B1. First,
theywerenotdetectedinhMSCs
lo-1a.Second,theywereblocked
in hMSCs
hi-1a by the pan-cytochrome P450 inhibitor ketocona-
zole, not like the effects of 1,25(OH)2D3, which were not affected
by ketoconazole. The antiapoptotic effects of 1,25(OH)2D3 or
25(OH)D3 in hMSCs
hi-1a are different from the proapoptotic
effects in some cancer cells
(4,10,33) and are similar to the effects in
other cell types. In ovarian cancer cells, 1,25(OH)2D3 inhibits
apoptosis that is mediated by death receptors.
(34) In rat
osteoblast-like osteosarcoma UMR 106 cells, 1,25(OH)2D3 elicited
antiapoptotic effects by decreasing the Bax/Bcl-2 ratio.
(11) There
are other antiapoptotic signals, as was reported for nongeno-
tropic mechanisms in osteoblasts and osteocytes.
(35) In sum, the
data indicate that the antiproliferative effects of 25(OH)D3 in
hMSCs
hi-1a and of 1,25(OH)2D3 in both samples of hMSCs are
explained by cell cycle arrest and not by increased apoptosis.
Calcitriol induces differentiation of many types of benign and
malignant cells.
(12,13,18,36–38) The differentiation of various cells,
including human myelomonocytic cells,
(9,29) induced by
1,25(OH)2D3 depends on the induction of p21
Waf1/Cip1. Further,
1,25(OH)2D3 is a key regulator of the reciprocal relationship
between proliferation and differentiation during the osteoblast
development sequence.
(39) Vitamin D or its analogues promote
osteoblastic differentiation, as shown for osteosarcoma cell lines
MG-63,
(40) HOS,
(23) SAOS,
(41) and TE85.
(41) Osteoblast differentia-
tion of human MSCs is stimulated by 1,25(OH)2D3 or 25(OH)D3 in
hMSCs
hi-1a, as shown here and elsewhere.
(17,18,37,38,42) As
expected, 25(OH)D3 failed to stimulate osteoblast differentiation
in hMSCs
lo-1a. Upregulation of osteoblast genes by 25(OH)D3 in
hMSCs
hi-1a was diminished by ketoconazole. Thus experiments
with ketoconazole indicate that both the antiproliferative and
prodifferentiation effects of 25(OH)D3 depend on CYP27B1.
Ketoconazole is a strong but differential inhibitor of both
CYP24A1 and CYP27B1
(43) and may be cytotoxic for some
cells.
(23) Those confounders may complicate interpretation of
results obtained with this agent. We therefore used the highly
specific technique of RNA interference to inhibit CYP27B1
expression in hMSCs
hi-1a. The level of synthesized 1,25(OH)2D3 in
the cells transfected with CYP27B1 siRNA was reduced to 22% of
that for cells transfected with nonsilencing siRNA. Osteoblast
differentiation of hMSCs
hi-1a by 25(OH)D3 was prevented upon
transfection with CYP27B1 siRNA, as indicated by osteoblast
signature gene expression and by AlkP enzymatic activity. These
findings are consistent with those from a study with HOS human
osteosarcoma cells in which silencing of CYP27B1 resulted in a
suppression of 25(OH)D3’s effects on those cells.
(23,44)
In conclusion, 25(OH)D3 has multiple effects in normal hMSCs;
it inhibits proliferation and promotes osteoblast differentiation
by mechanisms similar to those for 1,25(OH)2D3. Our data
indicate that antiproliferative and prodifferentiation effects of
25(OH)D3 in hMSCs require 1a-hydroxylase. There are sugges-
tions that other effects of 25(OH)D3 in other cell types, such as
induction of 24-hydroxylase in prostatic cells, may not require
1a-hydroxylase.
(45)ThreelinesofevidenceindicatethatCYP27B1
is required for the effects of 25(OH)D3 on hMSCs. Those effects
were not seen (1) in hMSCs with low constitutive expression of
CYP27B1, (2)inhMSCstreatedwith ketoconazole,or(3)inhMSCs
in which CYP27B1 expression was silenced. These findings
suggest that local osteoblast differentiation in vivo may be
promoted by 25(OH)D3 if the progenitor/precursor cells in
marrow express CYP27B1/1a-hydroxylase. We found that many
of hMSCs’ in vitro behaviors and baseline characteristics depend
on clinical features of the subjects from whom the cells were
EFFECTS OF 25(OH)D3 DEPEND ON CYP27B1 Journal of Bone and Mineral Research 1151isolated. The level of CYP27B1 expression in those cells depends
on vitamin D status and can be regulated by a number of factors,
including vitamin D.
(17) The combined presence of CYP27B1 and
theVDRinhMSCsindicatespossibleautocrine/paracrinerolesfor
25(OH)D3 to regulate osteoblast differentiation and skeletal
homeostasis.
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